Gail J. Roboz
NewYork–Presbyterian Hospital
444 Papers
1.6K Citations
Gail J. Roboz is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 339 publications. Previous affiliations of Gail J. Roboz include Cornell University & Boston Medical Center.
Chat about Author
Papers
A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).
Eric Padron,Amy E. DeZern,Kris Vaddi,Peggy Scherle,Qing Zhang,Yan Ma,Maria E. Balasis,Sara Tinsley,Hanadi Ramadan,Casandra Zimmerman,David P. Steensma,Gail J. Roboz,Jeffrey E. Lancet,Alan F. List,Mikkael A. Sekeres,Rami S. Komrokji +15 more
TL;DR: The first phase 1 clinical trial exploring the safety and efficacy of ruxolitinib, an FDA approved JAK1/2 inhibitor, in patients with CMML, found it to be safe and effective.
3
Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
John N. Allan,Gail J. Roboz,Eric J. Feldman,Joseph M. Scandura,Ellen K. Ritchie,Linda Lam,Wen Xie,Hsiao-Ting Hsu,Duane C. Hassane,Monica L. Guzman +9 more
TL;DR: Interleukin 2 receptor-α (CD25) expression on myeloid leukemic blasts may be a marker for chemotherapy-resistant leukemia stem cells and has been associated with poor overall survival in AML patients enrolled in a Phase I clinical trial combining the CXCR4 antagonist, plerixafor and the DNA methyltransferase inhibitor, decitabine.
3
Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Guillermo Garcia-Manero,Pierre Fenaux,Aref Al-Kali,Shyamala C. Navada,Maria R. Baer,Azra Raza,Peter L. Greenberg,Karl-Anton Kreuzer,Devendra K Hiwase,Gail J. Roboz,Valeria Santini,Uwe Platzbecker,Michael E. Petrone,Bernard H. Brownstein,Patrick S. Zbyszewski,Manoj Maniar,Lewis R. Silverman +16 more
TL;DR: All treatment-emergent adverse events (TEAEs) among patients with MDS/AML treated with rigosertib IV monotherapy, rigoertib oral mon Therapy, or in combination therapy were reviewed, overall and by grade of severity, and serious TEAEs and TEaes leading to discontinuation were reviewed.
3
Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.
Daniel A. Pollyea,Tracy I. George,Kathryn Foucar,Harry P. Erba,Michael A. Thompson,Mehrdad Abedi,Gail J. Roboz,Danny Landau,John M. Pagel,Karen Seiter,Christopher R. Cogle,Melissa Nifenecker,Arlene S. Swern,Pavel Kiselev,Mary M. Sugrue +14 more
TL;DR: Recurrent mutations in AML-associated genes have prognostic value and may help guide treatment decisions, and molecular genetic testing patterns for AML in clinical practice are largely dominated by single nucleotide polymorphism.
3
Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
Francine E. Garrett-Bakelman,Sheng Li,Stephen S. Chung,Todd Hricik,Rapaport Franck,Jay P. Patel,Richard Dillon,Priyanka Vijay,Anna L. Brown,Alexander E. Perl,B. Joy Cannon,Mathijs A. Sanders,Peter J. M. Valk,Lars Bullinger,Selina M. Luger,Michael W. Becker,Ian D. Lewis,L. Bik To,Richard J D'Andrea,David Grimwade,Ruud Delwel,Bob Löwenberg,Hartmut Döhner,Konstanze Döhner,Duane C. Hassane,Monica L. Guzman,Gail J. Roboz,Martin Carroll,Christopher Y. Park,Donna Neuberg,Ross L. Levine,Christopher E. Mason,Ari Melnick +32 more
TL;DR: It is proposed that epigenetic allele diversity allows populations of leukemia cells to sample transcriptional states more freely thus creating the potential for greater evolutionary fitness.
3